Table 6.
Author | Source population | Country | COPD definitiona | Year of study | Cohort size | Follow-up time (years) | Number of incident COPD patients (%) | Age range in years | IR COPD (per 1,000 PY) | Men (per 1,000 PY) | Women (per 1,000 PY) | Smoking prevalence, males (% of adults)b
|
|
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2000 | 2012 | ||||||||||||
Huhti et al21 | Non-selected population | Finland | Spirometry | 1961–1971 | 1,476 | 10 | 1,163 (78.7) | 40–64 | 2.0 and 10.0 for smokers | – | – | 34 | 25 |
Krzyzanowski et al23 | Longitudinal data, random sample | Poland | Spirometry | 1968–1981 | 4,612 | 13 | 112 (2.4) | 19–70 | 5.0 | – | – | 47 | 35 |
Vestbo and Lange25 | Population based | Denmark | Spirometry | 1976–1978 1981–1983 1992–1994 | 14,223 | 9 | – | ≥20 | 19 (5 years) and 9 (15 years) | – | – | 42 | 21 |
Johannessen et al22 | Participants selected via postal questionnaire (1985), a questionnaire (1987–1988), and spirometry (1996–1997) | Norway | Spirometry | 1985, 1987–1988, 1996–1997 | 908 | 12 | 40 (4.4) | 18–74 | 7 | – | – | 43 | 26 |
Terzikhan et al24 | Population based; embedded within the Rotterdam study | the Netherlands | Spirometry | RSI: 1989–1992 RSII: 2000–2003 RSIII: 2006–2009 | 14,619 | 10.7 | 1,304 (8.9) | ≥45 | 8.9 | 13.3 | 6.1 | 37 | 28 |
van Durme et al8 | Population based | the Netherlands | Spirometry/discharge letters | 1990–2004 | 7,983 | 11 | 648 (8.1) | ≥55 | 9.2 | 14.4 | 6.2 | 37 | 28 |
de Marco et al20 | ECRHS on random sample of young adults. Participants were invited by questionnaire. Of the responders, a random sample of 20% were invited for spirometry | Belgium, Denmark, Estonia, France, Germany, Iceland, Italy, the Netherlands, Norway, Spain, Sweden, Switzerland, UK | Spirometry | ECRHSI: 1991–1993 ECRHSII: 1999–2002 | 5,002 | 8.9 | 123 (2.4) | 20–44 | 2.8 | 3.2 | 2.4 | – | – |
Lindberg et al7 | Participants selected via postal questionnaire and a random sample was invited to a structured interview and spirometry in 1996 and 2003 | Sweden | Spirometry | Participated in 1996 and 2003 | 963 | 7 | 45 (≥GOLD II) (4.6) 91 (≥GOLD I) (9.4) | 46–77 | 6.7 GOLD II 13.5 GOLD I and more | – | – | 33 | 22 |
Kojima et al11 | Participants subjected to health checkups including spirometry | Japan | Spirometry | 1997–2005 | 17,106 | 8 | 466 (2.7) | 25–74 | 8.1 | 3.1 | 51 | 36 | |
Garcia Rodriguez et al26 | Population based | UK | Based on COPD-specific OXMIS and Read Codesc | 1996 | 808,513 | – | 1,927 (0.2) | 40–89 | 2.6 | – | – | 31 | 22 |
Gershon et al27 | Population based | Canada | ICD codes | 1996–2007 | 5–6.4 million | 12 | 61,998–55,903 | ≥35 | 1996: 11.8 2007: 8.5 | 1996: 13.9 2007: 9.4 | 1996: 10.4 2007: 7.8 | 29 | 20 |
Afonso et al9 | Population based | the Netherlands | Spirometry/medical records | 2000–2007 | 7,308 | 7 | 1,713 (23.4) | ≥40 | 2.92 | 3.54 | 2.34 | 37 | 28 |
Leem et al (current study) | Population based | Korea | Spirometry | 2001–2006 | 8,613 | 4 | 329 (3.8) | 40–69 | 15.50 | 30.08 | 5.52 | 62 | 52 |
Notes:
BTS criteria: FEV1/FVC ratio <0.70 and FEV1 <80% predicted; GOLD criteria: FEV1/FVC ratio <0.70.
Data from World Health Organization, Global Health Observatory Data Repository.
READ codes, current UK coding system for diseases.
Abbreviations: BTS, British Thoracic Society; ECRHS, European Community Respiratory Health Survey; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICD, International Classification of Diseases; OXMIS, Oxford Medical Information System; PY, person-years; RS, Rotterdam Study.